Tissue metabolite profiling identifies differentiating and prognostic biomarkers for prostate carcinoma

Abstract

Metabolomic research offers a deeper insight into biochemical changes in cancer metabolism and is a promising tool for identifying novel biomarkers. We aimed to evaluate the diagnostic and prognostic potential of metabolites in prostate cancer (PCa) tissue after radical prostatectomy. In matched malignant and nonmalignant prostatectomy samples from 95 PCa patients, aminoadipic acid, cerebronic acid, gluconic acid, glycerophosphoethanolamine, 2-hydroxybehenic acid, isopentenyl pyrophosphate, maltotriose, 7-methylguanine and tricosanoic acid were determined within a global metabolite profiling study using gas chromatography/liquid chromatography-mass spectrometry. The data were related to clinicopathological variables like prostate volume, tumor stage, Gleason score, preoperative prostate-specific antigen and disease recurrence in the follow-up. All nine metabolites showed higher concentrations in malignant than in nonmalignant samples except for gluconic acid and maltotriose, which had lower levels in tumors. Receiver -operating characteristics analysis demonstrated a significant discrimination for all metabolites between malignant and nonmalignant tissue with a maximal area under the curve of 0.86 for tricosanoic acid, whereas no correlation was observed between the metabolite levels and the Gleason score or tumor stage except for gluconic acid. Univariate Cox regression and Kaplan-Meier analyses showed that levels of aminoadipic acid, gluconic acid and maltotriose were associated with the biochemical tumor recurrence (prostate-specific antigen > 0.2 ng/mL). In multivariate Cox regression analyses, aminoadipic acid together with tumor stage and Gleason score remained in a model as independent marker for prediction of biochemical recurrence. This study proved that metabolites in PCa tissue can be used, in combination with traditional clinicopathological factors, as promising diagnostic and prognostic tools.

Chemical Isotope Labeling LC-MS for Monitoring Disease Progression and Treatment in Animal Models: Plasma Metabolomics Study of Osteoarthritis Rat Model

“…In a study of the dietary effect on long-term health including diabetes risk, 2-AAA was measured in human plasma along with several other metabolites and found to be 1.6 times higher after the beef meal than after the baked herring meal48. The level of 2-AAA was also found to be elevated in plasma of individuals with Alzheimer’s disease and mild cognitive impairment49 and prostate cancer tissue50. In a recent study of the role of gut microbiota in rheumatoid arthritis (RA), the level of 2-AAA was found to be increased in plasma samples of RA patients, compared to controls, and correlated with the abundance of Collinsella and production of the proinflammatory cytokine IL-17A51.…”

Synergistic action of image-guided radiotherapy and androgen deprivation therapy

“…[65][66][67][68][69][70][71][72] Future advances in the area of prognostic genomics could include the development of a gene signature that could enable clinicians to assign patients to treatment escalation (for example increasing the dose of IGRT that patients receive or a adding systemic therapy such as ADT) or de-escalation (with no requirement for systemic therapy) protocols on the basis of diagnostic biopsy, thus providing a priori information regarding a patient's likelihood of experiencing treatment failure. 73 The use of these invasive and/or noninvasive assays might help to better define the fraction of patients harbouring occult metastases whom could benefit from combined ADT-IGRT and improve their survival o utcomes (Box 2).…”

Prostate Specific Antigen. Current clinical application and future prospects

“…However thiosulfate has not been identified in the prostate cancer tissue as differentially expressed metabolite in malignant and benign prostate samples 67 .…”